



# VacZine Analytics

Bringing life to vaccine strategy...

## HPV vaccines

Country roll-out

October 2008

## HPV vaccine adoption: Western countries

National immunization programs

	When	Market type	Age group	Product
<b>US</b>	July 2006	NIP	9-26 yrs	Gardasil
<b>UK</b>	Sept 2006	NIP (Sept 08)	12-13yrs (14-18yrs)*	Cervarix
<b>France</b>	Sept 2006	NIP (Jan 08)	15-23yrs	Gardasil
<b>Germany</b>	Sept 2006	NIP (Mar 07)	12-17yrs	Gardasil
<b>Spain</b>	Sept 2006	NIP (Jan 08)		
<b>Italy</b>	Sept 2006	NIP (March 07)	12 yrs^	Gardasil
<b>Japan</b>	Sept 2007 (Filed)	TBA		Cervarix

Gardasil won positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe, July 2006

Cervarix won marketing authorization from the EMEA in September 2007

\*2-3 years catch-up campaign to start one year later in 2009

^Still available to other ages but on paid basis

## HPV vaccine adoption: other countries

National immunization programs/private market

	When approved/status	Market type <sup>#</sup>	Age group	Product
<b>Russia</b>	October 2008	Private	As label?	Cervarix
<b>China*</b>	Patent submitted in 2006. Approval in 5yrs?	Private	As label?	Gardasil
<b>India</b>	Under study (WHO)	Private	As label?	Gardasil
<b>Brazil</b>	August 2006	Private	As label?	Gardasil
<b>Mexico</b>	June 2006	Private	Girls 9-26 yrs	Cervarix/Gardasil
<b>Australia<sup>^</sup></b>	May 2007	NIP	Girls 9-26 yrs /10-45yrs Boys 9-15 yrs	Cervarix/Gardasil
<b>Canada</b>	July 2006	NIP	Girls 9-13 yrs /14-26yrs	Gardasil

\* [http://www.chinadaily.com.cn/world/2006-06/10/content\\_613557.htm](http://www.chinadaily.com.cn/world/2006-06/10/content_613557.htm)

<sup>^</sup>Australia was the first major market for Cervarix approval

<sup>#</sup> Or most predicted market type

## About VacZine Analytics:

VacZine Analytics is a brand new research consultancy based in the United Kingdom. Its aim is to provide high quality-disease and commercial analysis to those working within or in collaboration with the vaccine and biologics industry.

### With our product lines:

- DiseaseINFOPACK
- OpportunitySCAN
- MarketVIEW
- ExpertREACT
- VaccineSTATS

Our key focus is helping clients to build the case for developing new vaccines and biologics.

# Disclaimer

## All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.



# VacZine Analytics

Bringing life to vaccine strategy...

[www.vacZine-analytics.com](http://www.vacZine-analytics.com)

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel. +44 (0) 1279 654514

e-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

© VacZine Analytics, 2008. All rights reserved.